Niles, ILNCT07365995Now EnrollingIRB Ready

Metastatic Castration-resistant Prostate Cancer Clinical Trial in Niles, IL

Access cutting-edge metastatic castration-resistant prostate cancer treatment through this clinical trial at a research site in Niles. Study-provided care at no cost to qualified participants.

Sponsored by BioNTech SE

Quick Self-Assessment

See if you qualify for this Niles location

Preparing your pre-screening questions…

Expert Care in Niles

Access metastatic castration-resistant prostate cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related metastatic castration-resistant prostate cancer treatment provided free

Apply for This Niles Location

Check if you qualify for this metastatic castration-resistant prostate cancer clinical trial in Niles, IL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Niles

    Convenient for IL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Niles site if eligible
  4. 4Begin participation

About This Metastatic Castration-resistant Prostate Cancer Study in Niles

This study will test whether BNT324 is safe and works better against metastatic castration-resistant prostate cancer (mCRPC) than the current standard of care (SoC) chemotherapy, which is docetaxel (given together with the steroid medicines prednisone or prednisolone). The study will include participants with mCRPC that have been previously treated with androgen receptor pathway inhibitor, but with no previous taxane-based systematic chemotherapy for mCRPC. The main goals of this study are: * To find out if BNT324 helps participants live longer without their cancer getting worse (radiographic progression-free survival \[rPFS\]). * To find out if BNT324 helps participants live longer overall (overall survival \[OS\]).

Sponsor: BioNTech SE

Who Can Participate

Inclusion Criteria

Are male adults (defined as ≥18 years of age or of an acceptable age according to local regulations at the time of giving informed consent).
Must have documented progressive prostate cancer based on at least one of the following criteria:
Serum/plasma PSA progression, by local laboratory, defined as two consecutive increases in PSA over a previous reference value, each measured sequentially at least 1 week apart. The PSA value at screening is required to be ≥1.0 ng/mL.
Radiographic soft tissue progression as per PCWG3-modified RECIST v1.1.
Radiographic progression of bone disease: evaluable disease or new bone lesion(s) by bone scan per PCWG3 criteria.
Had previously received one or two prior androgen receptor pathway inhibitor treatments and experienced disease progression during or after a minimum of 8 weeks of therapy.
Must not have received systemic cytotoxic chemotherapy, including taxane-based chemotherapy, for mCRPC.
Must have had prior orchiectomy and/or have ongoing androgen-deprivation therapy and a castrate-level of serum/plasma testosterone (\<50 ng/dL or \<1.7 nmol/L). Participant being treated with luteinizing hormone-releasing hormone agonists or antagonists must continue such treatment throughout the study.
Must have an Eastern Cooperative Oncology Group performance score of 0 or 1. Key

Exclusion Criteria

Have received prior treatment with B7-H3 targeted therapy, including B7-H3 ADCs.
Have uncontrolled or significant cardiovascular disease, as defined in the protocol.
Have a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids or have current ILD/pneumonitis. NOTE: Other protocol defined Inclusion/Exclusion criteria apply.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Niles?

Yes, this clinical trial (NCT07365995) has an active research site in Niles, IL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Metastatic Castration-resistant Prostate Cancer Treatment Options in Niles, IL

If you're searching for metastatic castration-resistant prostate cancer treatment options in Niles, IL, this clinical trial (NCT07365995) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Niles research site is actively enrolling participants for this clinical trial. You'll receive care from experienced metastatic castration-resistant prostate cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all metastatic castration-resistant prostate cancer clinical trials near you to find additional studies recruiting in your area.

More Prostate Cancer Trials in Niles, IL

See all prostate cancer clinical trials recruiting in Niles — not just this study.

Browse Prostate Cancer Trials in Niles →

Browse More Trials by Condition

Prostate Cancer TrialsEssential Tremor TrialsRheumatoid Arthritis TrialsAnkylosing Spondylitis TrialsInterstitial Cystitis TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Niles?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Niles, IL